Developer · Ireland
Theravance Biopharma, Inc.
Biopharmaceutical company (Dublin, Ireland; formerly Nasdaq: TBPH) that co-commercializes YUPELRI (revefenacin) for COPD with Viatris. Spun out of Theravance, Inc. (now Innoviva) in 2014, taking TD-9855/ampreloxetine with it. After the Phase 3 CYPRESS failure (2026-03-03) it wound down its R&D function; it agreed to be acquired by Zymeworks on 2026-06-28 and the acquisition closed 2026-09-23, making it a wholly owned Zymeworks subsidiary.
Pipeline (1)
- Multiple System AtrophyDiscontinuedDiscontinued
- Attention-deficit/hyperactivity disorderDiscontinuedDiscontinued
- FibromyalgiaDiscontinuedDiscontinued
Deals & partnerships
- Jul 2022FinancingRoyalty Pharma invests up to $40M in ampreloxetine for MSARoyalty Pharma agreed to invest up to $40.0M ($25.0M upfront received July 2022, $15.0M on first regulatory approval) in exchange for 2.5%/4.5% royalties on ampreloxetine global net sales.
Catalysts · 0 upcoming · 5 reported
Recently reported
- 2026-03-03missed
AmpreloxetineforMultiple System AtrophyTopline data
Phase 3 CYPRESS did not meet its primary endpoint (change in OHSA composite score at Week 8 of the double-blind randomized-withdrawal period); secondary endpoints showed similar trends; consistent pressor effect, generally well tolerated, no supine-hypertension signal.
- 2022-04-30missed
AmpreloxetineforMultiple System AtrophyTopline data
REDWOOD Phase 3 did not meet its primary endpoint in the overall nOH population (PD, PAF, MSA); prespecified subgroup analysis suggested benefit driven by MSA patients.
- 2021-09-30missed
AmpreloxetineforMultiple System AtrophyTopline data
SEQUOIA 4-week Phase 3 RCT in symptomatic nOH did not meet its primary endpoint; no supine-hypertension signal.
- 2014-04-30met
AmpreloxetineforFibromyalgiaTopline data
TD-9855 20 mg met the primary endpoint (change in average daily pain score) and FIQ/PGIC secondaries vs placebo in fibromyalgia; 5 mg missed the primary.
- 2013-11-13missed
AmpreloxetineforAttention-deficit/hyperactivity disorderTopline data
TD-9855 did not meet the primary endpoint (AISRS total score vs placebo) at 5 mg or 20 mg in adult ADHD; ADHD program not continued.
Recent activity
- Mar 3, 2026ReadoutAmpreloxetine·Multiple System AtrophymissedPhase 3 CYPRESS did not meet its primary endpoint (change in OHSA composite score at Week 8 of the double-blind randomized-withdrawal period); secondary endpoints showed similar trends; consistent pressor effect, generally well tolerated, no supine-hypertension signal.source ↗
- Mar 3, 2026Phase changeAmpreloxetine·FibromyalgiaDiscontinuedInferred: Theravance announced complete wind-down of its R&D organization and the ampreloxetine program. Upper bound — de facto inactivity dates from ~2014.source ↗
- Jun 27, 2023Phase changeAmpreloxetine·Multiple System AtrophyPhase 3After SEQUOIA and REDWOOD missed in the mixed population, the program narrowed to MSA: CYPRESS (NCT05696717) start date per ClinicalTrials.gov (the 10-Q says initiated Q1 2023; registry start date used).source ↗
- Apr 30, 2022ReadoutAmpreloxetine·Multiple System AtrophymissedREDWOOD Phase 3 did not meet its primary endpoint in the overall nOH population (PD, PAF, MSA); prespecified subgroup analysis suggested benefit driven by MSA patients.source ↗
- Sep 30, 2021ReadoutAmpreloxetine·Multiple System AtrophymissedSEQUOIA 4-week Phase 3 RCT in symptomatic nOH did not meet its primary endpoint; no supine-hypertension signal.source ↗
- Jan 24, 2019Phase changeAmpreloxetine·Multiple System AtrophyPhase 3SEQUOIA (NCT03750552, Study 0169) first participant enrolled 2019-01-24 — start of the Phase 3 program.source ↗
- Sep 9, 2017Phase changeAmpreloxetine·Multiple System AtrophyPhase 2Phase 2 study 0145 (NCT02705755) in nOH (MSA, PD, PAF) started per ClinicalTrials.gov.source ↗
- Apr 30, 2014ReadoutAmpreloxetine·FibromyalgiametTD-9855 20 mg met the primary endpoint (change in average daily pain score) and FIQ/PGIC secondaries vs placebo in fibromyalgia; 5 mg missed the primary.source ↗
- Nov 13, 2013ReadoutAmpreloxetine·Attention-deficit/hyperactivity disordermissedTD-9855 did not meet the primary endpoint (AISRS total score vs placebo) at 5 mg or 20 mg in adult ADHD; ADHD program not continued.source ↗
- Nov 1, 2012Phase changeAmpreloxetine·FibromyalgiaPhase 2NCT01693692 started (month precision per CT.gov).source ↗
- Dec 1, 2011Phase changeAmpreloxetine·Attention-deficit/hyperactivity disorderPhase 2NCT01458340 started (month precision per CT.gov).source ↗
Competitive landscape
Other companies developing against Theravance Biopharma, Inc.'s targets or indications.
- Axsome Therapeutics, Inc.3 compoundsNETAttention-deficit/hyperactivity disorderFibromyalgia
- ABVC BioPharma, Inc.1 compoundNETAttention-deficit/hyperactivity disorder
- Otsuka Pharmaceutical Co., Ltd.1 compoundNETAttention-deficit/hyperactivity disorder
- Definium Therapeutics, Inc.1 compoundAttention-deficit/hyperactivity disorder
- Supernus Pharmaceuticals, Inc.1 compoundAttention-deficit/hyperactivity disorder
- Teva Pharmaceutical Industries Ltd.1 compoundMultiple System Atrophy
- Tonix Pharmaceuticals Holding Corp.1 compoundFibromyalgia